sorafenib has been researched along with novobiocin in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (novobiocin) | Trials (novobiocin) | Recent Studies (post-2010) (novobiocin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,271 | 15 | 290 |
| Protein | Taxonomy | sorafenib (IC50) | novobiocin (IC50) |
|---|---|---|---|
| DNA gyrase subunit B | Mycolicibacterium smegmatis MC2 155 | 0.046 | |
| DNA gyrase subunit B | Staphylococcus aureus | 0.0474 | |
| DNA gyrase subunit B | Streptococcus pneumoniae TIGR4 | 0.037 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.1441 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.1537 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 7.9 | |
| DNA gyrase subunit B | Mycolicibacterium smegmatis | 0.161 | |
| DNA gyrase subunit A | Staphylococcus aureus | 0.0383 | |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 0.0446 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 0.1315 | |
| DNA topoisomerase | Streptococcus pneumoniae | 2.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blagg, BS; Garg, G; Ghosh, S; Hall, JA; Seedarala, S; Zhao, H | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for sorafenib and novobiocin
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for sorafenib and novobiocin
| Article | Year |
|---|---|
Novobiocin Analogues That Inhibit the MAPK Pathway.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mitogen-Activated Protein Kinases; Models, Molecular; Molecular Structure; Novobiocin; Signal Transduction; Structure-Activity Relationship | 2016 |